Novo Nordisk A/S - share repurchase programme
Rhea-AI Summary
Novo Nordisk (NYSE:NVO) reports progress on its ongoing share repurchase programme conducted under EU Safe Harbour rules. The 12‑month programme, running from 4 February 2026, targets up to DKK 15 billion of B share buybacks. A sub-programme initiated on 6 May 2026 allows repurchases of up to DKK 11,200,000,010.45 through 1 February 2027.
Between 17–21 August 2026, Novo Nordisk bought 1,045,000 B shares at average prices around DKK 293–299, bringing accumulated repurchases under the May programme to 15,170,000 shares for DKK 4,590,476,842. As of 21 August 2026, the company has repurchased 29,929,179 B shares since 4 February 2026, for DKK 8,390,476,831 at an average price of DKK 280.34 per share. Novo Nordisk now holds 43,969,876 B shares as treasury shares, equal to 1.0% of its 4,465,000,000 total A and B shares.
Positive
- DKK 15 billion targeted buybacks over 12 months from 4 February 2026
- Repurchased 29,929,179 B shares since 4 February 2026 for DKK 8,390,476,831
- Treasury position at 43,969,876 B shares, representing 1.0% of share capital
- Recent week purchases of 1,045,000 B shares support ongoing capital return
Negative
- Up to DKK 15 billion of capital committed to share repurchases over the programme period
AI-generated analysis. How Rhea-AI works. Not financial advice.
Bagsværd, Denmark, 24 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 17 August, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 14,125,000 | 4,281,660,830 | |
| 17 August 2026 | 205,000 | 292.63 | 59,989,440 |
| 18 August 2026 | 210,000 | 292.60 | 61,446,140 |
| 19 August 2026 | 210,000 | 296.16 | 62,193,344 |
| 20 August 2026 | 210,000 | 299.08 | 62,807,428 |
| 21 August 2026 | 210,000 | 297.05 | 62,379,660 |
| Accumulated under the programme | 15,170,000 | 4,590,476,842 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 43,969,876 B shares of DKK 0.10 as treasury shares, corresponding to
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 21 August 2026, Novo Nordisk has since 4 February 2026 repurchased a total 29,929,179 B shares at an average share price of DKK 280.34 per B share equal to a transaction value of DKK 8,390,476,831.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com |
| Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Alex Bruce +45 3444 2613 axeu@novonordisk.com | Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
| Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com | Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
| Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 52 / 2026
Attachments
